Le T. N. Anh
Research Subjects
Research Interests
Le T. N. Anh has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Agnes Gebhard
KNCV Tuberculosis Foundation, 2596 BC The Hague, The Netherlands
1 shared publication - Ajay M. V. Kumar
International Union Against Tuberculosis and Lung Disease, 2 Rue Jean Lantier, 75001 Paris, France
1 shared publication - Giang Hoai Nguyen
Interactive Research and Development, Ho Chi Minh 700000, Vietnam
1 shared publication - Gomathi Ramaswamy
Community Medicine and Family Medicine , All India Institute of Medical Sciences , Bibinagar , Telangana, India
1 shared publication - Hoa Binh Nguyen
Vietnam National Lung Hospital, Hanoi 10000, Vietnam
1 shared publication - Mamel Quelapio
Tropical Disease Foundation, Makati, Philippines
1 shared publication
Latest Publications
- Open Access
- 10 March 2020
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 5 (1) , 43
High Levels of Treatment Success and Zero Relapse in Multidrug-Resistant Tuberculosis Patients Receiving a Levofloxacin-Based Shorter Treatment Regimen in Vietnam
Vietnam has been using a levofloxacin-based shorter treatment regimen (STR) for rifampicin resistant/multidrug-resistant tuberculosis (RR/MDR-TB) patients since 2016 on a pilot basis. This regimen lasts for 9–11 months and is provided to RR/MDR-TB patients without second-line drug resistance. We report the treatment outcomes and factors associated with unsuccessful outcomes. We conducted a cohort study involving secondary analysis of data extracted from electronic patient records maintained by the national TB program (NTP). Of the 302 patients enrolled from April 2016 to June 2018, 259 (85.8%) patients were successfully treated (246 cured and 13 ‘treatment completed’). Unsuccessful outcomes included: treatment failure (16, 5.3%), loss to follow-up (14, 4.6%) and death (13, 4.3%). HIV-positive TB patients, those aged ≥65 years and patients culture-positive at baseline had a higher risk of unsuccessful outcomes. In a sub-group of patients enrolled in 2016 (n = 99) and assessed at 12 months after treatment completion, no cases of relapse were identified. These findings vindicate the decision of the Vietnam NTP to use a levofloxacin-based STR in RR/MDR-TB patients without second-line drug resistance. This regimen may be considered for nationwide scale-up after a detailed assessment of adverse drug events.
- 10 March 2020
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 5 (1) , 43
Open AccessHigh Levels of Treatment Success and Zero Relapse in Multidrug-Resistant Tuberculosis Patients Receiving a Levofloxacin-Based Shorter Treatment Regimen in Vietnam
Vietnam has been using a levofloxacin-based shorter treatment regimen (STR) for rifampicin resistant/multidrug-resistant tuberculosis (RR/MDR-TB) patients since 2016 on a pilot basis. This regimen lasts for 9–11 months and is provided to RR/MDR-TB patients without second-line drug resistance. We report the treatment outcomes and factors associated with unsuccessful outcomes. We conducted a cohort study involving secondary analysis of data extracted from electronic patient records maintained by the national TB program (NTP). Of the 302 patients enrolled from April 2016 to June 2018, 259 (85.8%) patients were successfully treated (246 cured and 13 ‘treatment completed’). Unsuccessful outcomes included: treatment failure (16, 5.3%), loss to follow-up (14, 4.6%) and death (13, 4.3%). HIV-positive TB patients, those aged ≥65 years and patients culture-positive at baseline had a higher risk of unsuccessful outcomes. In a sub-group of patients enrolled in 2016 (n = 99) and assessed at 12 months after treatment completion, no cases of relapse were identified. These findings vindicate the decision of the Vietnam NTP to use a levofloxacin-based STR in RR/MDR-TB patients without second-line drug resistance. This regimen may be considered for nationwide scale-up after a detailed assessment of adverse drug events.